% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • treblehook_treblehook treblehook_treblehook Dec 9, 2010 8:35 AM Flag


    anyone? anyone? TIA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • you said it. too cold for me to go fishing. in Jan I'll go overseas for 2 months to cscape this cold maybe a little fishing over there.

    • 4.4 m shares, so far, in Stockholm.

    • Here's a translation of an article that appeared in Swedish. Dunno if this is the cause:

      EpiCept steals the show

      There was another biotech stock that stole the show from Active Biotech today. EpiCept. Share rushes, sometimes over 50 percent, since the Rodman & Renshaw reiterate its a buy for the Swedish-American biotechnology company. The target price is $ 2, or just under 14 dollars.

      The background is a meta-analysis, therefore, an analysis of previously conducted clinical trials, which EpiCept presented at a scientific congress. Using two statistical models, researchers have found that EpiCept cancer drug Ceplene and interleukin-2 has an advantage over standard therapy and interleukin-2.

      That year's sharp price fall in EpiCept been an overreaction on the FDA's requirement that additional studies are required for approval in the U.S., VA has previously pointed out. Although there remains considerable risk in shares has the potential far from reflects the value of the European market where Ceplene in fact already approved.

      • 1 Reply to dharma_bear
      • here's another. couldn't find this on Bloomberg directly:

        Swedish to English translation
        (Bloomberg) Rodman & Renshaw reiterates outperform recommendation on EpiCept after the company unveiled a study at the ASH conference. The target price is $ 2, corresponding to 13:72 crowns, implying a significant upside to Wednesday's closing price of SEK 3:09.

        According to a sector analysis dated December 8.

        EpiCept presented results from a meta-analysis of Ceplene with interleukin-2 (IL-2), a study that was part of the company's filing for Ceplene. Using two statistical models, researchers have found that Ceplene and IL-2 has an advantage over the standard treatment and IL-2.

        "It should be noted that this conclusion is robust with respect to modeling assumptions," said Rodman & Renshaw.

        Rodman & Renshaw concluded that the observed leukemia-free survival of Ceplene and IL-2 over IL-2 and standard treatment is clinically relevant and should generate interest in immunotherapy as a means of maintaining the regression and prevent relapse in AML patients.

0.3812-0.0598(-13.56%)Jun 24 4:00 PMEDT